Neuroprotective study of Nigella sativa-loaded oral provesicular lipid formulation: In vitro and ex vivo study

Drug Delivery

Volumn 21, Issue 6, 2014, Pages 487-494

  Akhtar, Mohd ^a   Imam, Syed Sarim ^b   Afroz Ahmad, Mohd ^a   Najmi, Abul Kalam ^a   Mujeeb, Mohd ^b   Aqil, Mohd ^b  

^a Department of Pharmacology ^*  (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Lipid formulation; Neuroprotective; Nigella Sativa; Oral

Indexed keywords

CHOLESTEROL; NIGELLA SATIVA EXTRACT; NIOSOME; NONIONIC SURFACTANT; PHOSPHATIDYLCHOLINE; PRONIOSOME; UNCLASSIFIED DRUG; LIPID; LIPOSOME; NEUROPROTECTIVE AGENT; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLACK CUMIN; BRAIN ISCHEMIA; CHEMICAL COMPOSITION; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG RELEASE; EX VIVO STUDY; FILM; GRIP STRENGTH; IN VITRO STUDY; IN VIVO STUDY; KINETICS; LIPID PEROXIDATION; LOCOMOTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PERMEABILITY; PHYSIOLOGY; PROCEDURES; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; LIPIDS; LIPOSOMES; NEUROPROTECTIVE AGENTS; NIGELLA SATIVA; PARTICLE SIZE; PERMEABILITY; PHOSPHATIDYLCHOLINES; RATS; RATS, WISTAR; SURFACE-ACTIVE AGENTS;

EID: 84906222518     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.886640     Document Type: Article

References (33)

1. Abdulhakeem A, Majed A, Fadhel A, et al. (2006). Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur J Phar 543:40-7.
2. Aboul-Enein HY, Abou-Basha LI. (1995). Simple HPLC method for the determination of thymoquinone in black seed oil (Nigella Sativa Linn). J Liquid Chrom 18:895-902.
3. Akhtar M, Maikiyo AM, Khanam R, et al. (2012). Ameliorating effect of two extracts of Nigella sativa on middle cerebral artery occluded rats. J Pharm Bio Allied Sci 4:70-5.
4. Akhtar M, Maikiyo AM, Najmi AK, et al. (2013). Neuroprotective effects of chloroform and petroleum ether extracts of Nigella sativa seeds in cerebral ischemia. J Pharm Bio Allied Sci 5:119-25.
5. Akhtar M, Pillai KK, Vohra D. (2008). Effects of thioparamide on oxidative stress markers in middle cerebral artery occlusion model of focal cereal ischemia in rats. Hum Exp Tox 27:761-7.
6. Ali A, Ahmed FJ, Pillai KK, Vohora D. (2004). Evidence of antiepileptic potential of amiloride with neuropharamacological benefits in rodents models of epilepsy and behaviour. Epilepsy Behav 5:322-8.
7. Ali BH, Blunden G. (2003). Pharmacological and toxicological properties of Nigella sativa. Phytother Res 17:299-305.
8. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. (2005). Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 59:485-90.
9. Babazadeh B, Sadeghnia HR, Kapurchal ES, et al. (2012). Protective effect of Nigella sativa and thymoquinone on serum/glucose deprivation-induced DNA damage in PC12 cells. Avic J of Phytomed 2: 125-32.
10. Balakrishnan P, Shanmugam S, Lee WS, et al. (2009). Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm 377:1-8.
11. Burits M, Bucar F. (2000). Antioxidant activity of Nigella sativa essential oil. Phytother Res 14:323-8.
12. Carr RL. (1965). Evaluation flow properties of solids. Chem Eng 72: 163-8.
13. Claiborne A, Greenworld RA. (1985). Handbook of method of oxygen free radical research. Boca Raton, Florida: CRC Press; 283-5.
14. Ellman GL. (1959). Tissue sulphhydryl groups. Arc Biochem Biophy 82: 70-3.
15. Gurrapu A, Jukanti R, Bobbala SR, et al. (2012). Improved oral delivery of valsartan from maltodextrin based proniosome powders. Advan Powder Tech 23:583-590.
16. Hu C, Rhodes DG. (1999). Proniosomes: a novel drug carrier preparation. Int J Pharm 185:23-35.
17. Janga KY, Jukanti R, Velpula A, et al. (2012). Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. Eur J Pharm Biopharm 80:347-357.
18. Jukanti R, Sheela S, Bandari S, Veerareddy PR. (2011). Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J Pharm Sci 100:3208-3222.
19. Kagiyama T, Kagiyama S, Phillips MI. (2003). Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats. Regul Pept 110:241-7.
20. Lannert H, Hcfyer S. (1998). Intracerebroventricular administration of streptozotocin causes long term diminution in learning and memory abilities and intracerebral energy metabolism in adult rats. Stroke 28: 2060-6.
21. Lobenberg G. Amidon L. (2000). Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50:3-12.
22. Longa EZ, Carlson S, Cummins R. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91.
23. Lowry OH, Rosenburg NJ, Farr AL, Randale RJ. (1951). Protein measurement with folin phenol reagent. J Biol Chem 193:265-75.
24. Nasr M. (2010). In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. AAPS Pharm Sci Tech 11:85-9.
25. Ohkawa H, Ohishi N, Yagi K. (1979). Assay of lipid peroxides in animals tissue by thiobarbituraic acid reaction. Anal Biochem 95:351-8.
26. Pando D, Gutierrez G, Coca J, Pazos C. (2013). Preparation and characterization of niosomes containing resveratrol. J Food Eng 117: 227-34.
27. Plessis J, Ramachandran C, Weiner N, Miller DG. (1991). The influence of particle size of liposomes on deposition of drug into skin. Int J Pharm 103:277-82.
28. Porter CJH, Trevaskis NL, Charman WN. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Dis 6:231-48.
29. Pratap R, Pillai KK, Khanam R, et al. (2011). Protective effect of irbesartan an angiotensin II receptor antagonist alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. Hum Exp Tox 30: 354-62.
30. Sentjurc M, Vrhovnik K, Kristl J. (1999). Liposomes as a topical delivery system: the role of size on transport studied by the EPR imaging method. J Control Rel 59:87-97.
31. Staniforth J. (2002). Powder flow. In: Aulton M, ed. Pharmaceutics. The science of dosage form design. 2nd ed. Edinburgh: Churchill Livingstone, Longman Group, 197-210.
32. Staniforth JN. (1988). Pharmaceutics. In: Aulton ME, ed. The science dosage form design. Churchill: Livingstone, 610-36.
33. Szuts M, Szucs IB, Eros N, et al. (2010). Study of gel forming properties of sucrose esters for thermosensitive drug delivery systems. Int J Pharm 383:132-7.